TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07463183: A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT07463183 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07463183 Rescue Dossier →